ADIPQ gene polymorphism rs266729 (-11377 C>G) and metabolic syndrome risk in a Mexican population of western Mexico

El polimorfismo rs266729 (-11377 C>G) del gen ADIPQ y el riesgo de síndrome metabólico en una población mexicana del occidente de México

Mayra Judith García Robles¹, Jaqueline Camarillo Alba², Manuel de Jesús Valenzuela Gurrola³, Jesús Adrián López³, and Saúl Ramírez de los Santos⁴

¹Department of Biotechnology. Universidad Politécnica de Zacatecas. Fresnillo, Zacatecas. Mexico. ²Biotechnology Engineering Program. Universidad Politécnica de Zacatecas. Fresnillo, Zacatecas. Mexico. ³MicroRNA Laboratory. Unidad Académica de Ciencias Biológicas. Universidad Autónoma de Zacatecas. Zacatecas, Mexico. ⁴Department of Clinics. Centro Universitario de Los Altos. Universidad de Guadalajara. Tepatitlán de Morelos, Jalisco. Mexico

Abstract

Introduction: obesity often leads to deregulation and disrupting of the function of adipokines, which leads to various altered conditions, including metabolic syndrome (MetS). Adiponectin is one of the main adipokines secreted by adipocytes. The ADIPQ gene polymorphism rs266729 (-11377 C>G) is significantly associated with metabolic alterations related to obesity in different populations. Mexico has a high prevalence of obesity and risk factors associated with MetS. We investigated the association of the ADIPQ gene polymorphism rs266729 (-11377 C>G) with MetS in a Mexican population of western Mexico.

Methods: a total of 101 MetS patients and 70 unrelated healthy subjects were genotyped for ADIPQ polymorphism rs266729 using the restriction fragment length polymorphism method.

Results: we found a higher frequency of the minor allele G in MetS patients, as compared to that observed in the control group (OR = 2.17; 95 % CI, 1.26-3.70; p = 0.003). Also, the GG genotype was significantly associated with MetS risk under codominant (OR = 4.0; 95 % CI, 1.32-11.71; p = 0.014), dominant (OR = 2.16; 95 % CI, 1.12-4.03; p = 0.018), and recessive (OR = 3.33; 95 % CI, 1.14-9.45; p = 0.033) genetic models.

Conclusion: our findings suggest that the minor allele G in the ADIPQ gene polymorphism rs266729 constitutes a risk factor for the development of MetS in a Mexican population of western Mexico.

Acknowledgements: the authors are particularly grateful to Dr. Mario Pérez Mejía and MCE Angélica Meza Montalvo for their support in the performance of the present project.

Disclosure statement: the authors have no conflicts of interest to declare.

Funding sources: this research received no external funding.

Author contributions: MJGR to conceptualization; JCA and MJVG to methodology; MJGR and MJVG to formal analysis; MJGR and JAL to resources; MJGR and JCA to writing and original draft preparation; MJGR, JAL, SRLleS to writing, reviewing & editing; MJGR to supervision and project administration. All authors read and approved the final manuscript.

Received: 07/06/2020 • Accepted: 26/10/2020

Correspondence: Mayra Judith García Robles. Departamento de Biotecnología. Universidad Politécnica de Zacatecas. Plan de Pardillo Sn, Parque Industrial. 99059 Fresnillo, Zacatecas. Mexico. e-mail: gamaju21@yahoo.com
INTRODUCTION

Obesity is a public health problem worldwide. In 2016, more than 1.9 billion adults, 18 years and older, were overweight. Of these, over 650 million were obese (1). Mexico presents a high prevalence of obesity. The ENSANUT MC, 2016 reported that the prevalence of abdominal obesity was 76.6%, this being higher in women than in men (87.7% vs. 65.4%) and in the group of 40- to 79-year-olds as compared with the group of subjects aged 20 to 29 years (2). According to Rtveladze et al., by 2050 in Mexico, there will be a greater population with obesity, as well as a considerable increase in cases of diabetes and cardiovascular diseases (3). Obesity is often associated with insulin resistance and the metabolic syndrome. Metabolic syndrome (MetS) is characterized by the accumulation of physiological, biochemical, clinical, and metabolic disorders that increase the risk of diseases related to obesity such as atherosclerotic cardiovascular disease and diabetes mellitus type 2, as well as mortality. The prevalence of MetS at a global level differs according to sex, age, race, and ethnicity of the population studied, and also on the basis of the definition of MetS that is used for diagnosis (4). There are various criteria for the diagnosis of MetS, with the National Cholesterol Education Programme Adult Treatment Panel III (NCEP ATP III), and the International Diabetes Federation (IDF), which considers the ethnic and regional characteristics of patients, being among the most widely used sets (4,5). The adipose tissue participates actively in maintaining energy homeostasis through the secretion of adipokines. It is important to note that obesity often leads to deregulation and disrupting of the function of adipokines, which leads to various alterations including the metabolic syndrome (6). Adiponectin is one of the main adipokines secreted by adipocytes. The gene ADIPOQ is located on chromosome 3q27 and is composed of three exons (7). Several studies have shown that adiponectin exerts the following functions that are beneficial to homeostasis: improves overall insulin sensitivity, enhances energy consumption and fatty acid oxidation, has anti-inflammatory and anti-oxidant properties, and contributes to cardiovascular protection (8). There is evidence of a connection between the 3q27 locus with type-2 diabetes, obesity, and metabolic syndrome (7). Several single nucleotide polymorphisms (SNPs) have been identified in ADIPOQ. Among these variations, the SNP -11377 C>G is located in the promoter region of the gene. The minor allele G alters the sequence of the binding site for SP1, which causes a loss of SP1 binding effect, probably affecting adiponectin promoter transcription activity (9). Studies in different populations have linked this SNP with metabolic alterations related to obesity (7,10). Mexico has a high prevalence of obesity and of risk factors associated with MetS. Thus, the objective of this study was to determine the allelic and genotype distribution of the ADIPOQ gene polymorphism rs266729 (-11377 C>G) and its association with MetS in a Mexican population of western Mexico.

MATERIALS AND METHODS

STUDY POPULATION

We performed a descriptive, cross-sectional study. The population included 101 patients diagnosed with metabolic syndrome according to the ATP III criteria (11), who attended Centro de Salud Fresnillo 2 in Zacatecas, México, and 70 unrelated healthy subjects.

The study protocol was approved by the Institutional Ethics Committee (6/2017-2018). All participants provided their written informed consent, and the study was performed in accordance with the Helsinki Declaration (12).

ANTHROPOMETRIC PARAMETERS AND BLOOD COLLECTION

The values of height and weight for each participant were used to calculate their body mass index (BMI) (kg/m²). Also measured were the circumference of the waist and hip, and the waist-hip
ratio. Finally, venous blood samples were collected from all study participants. The quantification of serum adiponectin levels will be performed in the next stage of the study.

**GENOTYPING**

Genomic DNA was extracted from peripheral blood leukocytes using a standard salting out method (13). The analysis of the ADIPQ -11377 C>G polymorphism was performed using a polymerase chain reaction and restriction fragment length polymorphism (PCR-RFLP) method (10).

Briefly, PCR amplification (SureCycler 8800 thermal cycler) of a 334-bp fragment of the ADIPQ gene was carried out using a forward primer: GGTGACCTTACCTTACTG, and a reverse primer: TAGAAGGAGCCCTGGAGAA. A 50 μL PCR reaction mixture containing 2 μL of genomic DNA, 10 μL of 10x Buffer Reaction (My Taq™ DNA polymerase, BIOLINE), 1.5 μL each of forward and reverse primers, 0.5 μL of My Taq DNA polymerase (My Taq™ DNA polymerase, BIOLINE), and 34.5 μL of water. The PCR conditions were as follows: an initial denaturation at 95 °C for 5 min, followed by 35 cycles, denaturation at 95 °C for 30 s, annealing at 60 °C for 30 sec, extension at 72 °C for 40 sec, and final extension at 72 °C for 4 min. Amplified fragments were analyzed through 6 % polyacrylamide gel electrophoresis stained with silver staining. The genotyping PCR products were digested with the restriction enzyme HhaI (New England Biolabs). The results of the genotyping were the following: CC genotype (334 bp), CG genotype (334, 212, and 122 bp) and GG genotype (212 and 122 bp).

**STATISTICAL ANALYSIS**

A descriptive analysis of the data (mean, standard deviation, frequency of genotypes and alleles, and contingency tables) and subsequently an inferential analysis (χ² test, Student’s t-test, and odds ratio with a confidence interval at 95 %) were carried out. These statistical analyses were performed using the software programs Prism 7 and IBM SPSS, version 25.0 for Mac OS X. Significance was assumed for p < 0.05.

**RESULTS**

In the present study, a total of 171 people were enrolled, 101 MetS patients (mean age, 52.57 ± 13.1) and 70 unrelated healthy subjects (mean age, 39.25 ± 9.0). Table I shows their demographic characteristics.

The distributions of ADIPQ -11377 C>G genotypes are shown in table II. The control group was found in Hardy-Weinberg equilibrium.

**Table I. Demographic characteristics of the study subjects**

| Characteristics | MetS (n = 101) | Controls (n = 70) | p     |
|-----------------|---------------|------------------|-------|
| Age (years)*    | 52.57 ± 13.1  | 39.25 ± 9.0      | < 0.0001|
| Height (meters)*| 1.6 ± 0.84    | 1.6 ± 0.10       | 0.1430 |
| Weight (kg)*    | 80.00 ± 13.61 | 73.10 ± 17.97    | 0.0075 |
| BMI (kg/m²)*    | 31.22 ± 4.62  | 27.43 ± 5.91     | < 0.0001|
| WC (cm)*        | 100.0 ± 11.37 | 91.94 ± 17.53    | 0.0010 |
| HC (cm)*        | 105.31 ± 11.55| 100.98 ± 18.29   | 0.0828 |
| W:H*            | 0.95 ± 0.05   | 0.91 ± 0.05      | < 0.0001|

**Table II. Distributions of ADIPQ -11377 C>G genotypes and alleles in MetS patients and control subjects**

| Genotypes | MetS (n = 101) | Controls (n = 70) | χ² | p    | OR (95 % CI) | p    |
|-----------|---------------|------------------|----|------|--------------|------|
| CC        | 49            | 47               | 7.43 | 0.024 |              |      |
| CG        | 35            | 19               | 7.43 | 0.024 |              |      |
| GG        | 17            | 4                | 5.7  | 0.143 |              |      |

Categorical variables were compared using the χ² test. Odds ratios (OR) and 95 % confidence intervals (CI) were used for the assessment of risk factors. Significance level: p < 0.05.
librium with a $p = 0.283$, whereas the group with MetS obtained a value of 0.021. The homozygous GG genotype was found to be more frequent in MetS patients (16.9 % for MetS vs 5.7 % for controls). The comparison between both groups showed that homozygous GG genotypes were significantly higher in patients than in controls ($\chi^2 = 7.43$, $p = 0.024$). Furthermore, we found a higher frequency of the allele G in MetS patients (34.2 %), as compared to what we observed in the control group (19.3 %) (OR = 2.17; 95 % CI: 1.26-3.70; $p = 0.003$).

The genetic model analysis showed that individuals carrying the GG genotype were at increased risk of MetS as compared to those with the CC genotype (OR = 4.0; 95 % CI: 1.32-11.71; $p = 0.014$). The CC + GG genotype (dominant model) showed a statistically significant correlation with MetS when compared to the CC genotype (OR = 2.16; 95 % CI: 1.12-4.03; $p = 0.018$), whereas the GG genotype (recessive model) was significantly associated with MetS risk when compared to the CC + CG genotype (OR = 3.33; 95 % CI: 1.14-9.45, $p = 0.033$) (Table III).

**DISCUSSION**

In the present study, we report an association between the ADIPQ -11377 C>G genetic polymorphism and susceptibility to metabolic syndrome. Previous studies have shown that people with obesity and diabetes, as well as MetS, often have low levels of adiponectin in the serum or plasma (14-17). It is clear from current research that the levels of adipokines are influenced by body fat and inflammatory states, for example; in the particular case of adiponectin, in vitro and in vivo studies showed that tumor necrosis factor alpha (TNF-α) suppresses the multimerization and secretion of adiponectin (18). Likewise, obesity-induced adipocyte hypertrophy results in a shift in adipokine production from adiponectin to leptin (19). In fact, it has been proposed that adiponectin may have an important role in the pathogenesis of MetS (20). However, it is relevant to consider the genetic factors that could contribute to the variations seen in serum/plasma concentrations.

The ADIPQ -11377 C>G polymorphism is located in the promoter region of the ADIPQ gene (21). Reports in various populations of the world have shown an association of the ADIPQ -11377 C>G polymorphism with metabolic alterations related to obesity (7,10,22,23). In contrast, other studies have shown conflicting results with respect to the allele associated with type-2 diabetes (24), or even when the study population is classified by gender (9). From another point of view, it would be important to evaluate whether the polymorphism has an impact on the modification of MetS components and other obesity-related diseases after a change in lifestyle such as a dieting. In this context, de Luis et al. showed that after weight loss, the CC genotype of the ADIPQ -11377 C>G polymorphism was associated with increases in adiponectin levels and decreases in low-density lipoprotein cholesterol, insulin, and homeostasis model assessment for insulin resistance after weight loss (25). Specifically, it was evident that after a monounsaturated fat-enriched diet, only subjects with the CC genotype showed significant improvements in total cholesterol (CC vs. CG + GG) (−9.0 ± 1.1 mU/L vs. −4.5 ± 2.4 mg/dL, $p = 0.01$), LDL cholesterol (−6.0 ± 1.1 mg/dL vs. −3.0 ± 0.9 mg/dL, $p = 0.03$), glucose (−4.7 ± 1.1 mg/dL vs. −0.6 ± 0.5 mg/dL, $p = 0.01$), and insulin levels (−2.6 ± 1.0 mU/L vs. −0.7 ±

**Table III. Association between the ADIPQ -11377 C>G genetic polymorphism and susceptibility to metabolic syndrome**

| Model and genotype | MetS (n = 101) | Controls (n = 70) | $\chi^2$ | P | OR (95 % CI) | P |
|--------------------|---------------|------------------|----------|---------------|------------------|---------------|
| Codominant         |               |                  |          |               |                  |               |
| CC                 | 49            | 48.5             | 47       | 67.1          | 1.0 (Reference)  |               |
| CG                 | 35            | 34.6             | 19       | 27.1          | 2.66 (0.102)     | 1.7 (0.86-3.61) |
| GG                 | 17            | 16.9             | 4        | 5.7           | 6.27 (0.012)     | 4.0 (1.32-11.71) |
| Dominant           |               |                  |          |               |                  |               |
| CC                 | 49            | 48.5             | 47       | 67.1          | 1.0 (Reference)  |               |
| CG+GG              | 52            | 51.5             | 23       | 32.9          | 5.827 (0.015)    | 2.16 (1.12-4.03) |
| Recessive          |               |                  |          |               |                  |               |
| CC+CG              | 84            | 83.2             | 66       | 94.3          | 1.0 (Reference)  |               |
| GG                 | 17            | 16.8             | 4        | 5.7           | 4.744 (0.029)    | 3.33 (1.14-9.45) |

Categorical variables were compared using the $\chi^2$ test. Odds ratios (OR) and 95 % confidence intervals (CI) were used for the assessment of risk factors. Significance level: $p < 0.05$. 

Nutr Hosp 2021;38(1):67-72
The trend continues with different diet treatments (26,27). After a polyunsaturated fat-enriched diet in all parameters. The 0.3 mU/L, p = 0.02), as well as in HOMA-IR (−0.5 ± 0.2 units vs. −0.2 ± 0.4 units, p = 0.03). The same improvement was reported after a polynsaturated fat-enriched diet in all parameters. The trend continues with different diet treatments (26,27).

One interventional study in 60 extremely obese patients who were evaluated 32 months after bariatric surgery showed that SNPs in ADIPOQ gene were associated with changes in metabolic variables in obse individuals; for example, C-allele homozygotes presented a higher reduction in LDL cholesterol, total cholesterol, and triglycerides than carriers of the variant G-allele (28).

Few studies have focused on the relationship of this SNP with MetS. In the present study, the proportions found of the CC, CG, and GG genotypes in patients with MetS were the following: 48.5 %, 34.6 %, and 16.9 %, respectively, whereas in the control group the frequency of the GG genotype was only 5.6 %. Even though in an Italian population the genotype distribution of the group with MetS was comparable (CC, 38 %; CG, 33 %; and GG, 28 %) to that observed in our study, the control group showed a greater frequency for the GG genotype (40 %). On the other hand, a meta-analysis that evaluated the association between ADIPOQ polymorphisms and MetS in a Chinese population found no association with the ADIPOQ rs266729 polymorphism in any of the analyzed genetic models (allele model: OR = 0.98; 95 % CI: 0.82-1.17; dominant model: OR = 0.90; 95 % CI: 0.79-1.02; recessive model: OR = 1.09; 95 % CI: 0.85-1.39; homozygote model: OR = 1.03; 95 % CI: 0.80-1.33) (29). We found that the GG genotype was significantly associated with MetS risk under the codominant (OR = 4.0; 95 % CI: 1.32-11.71; p = 0.014), dominant (OR = 2.16; 95 % CI: 1.12-4.03; p = 0.018), and recessive (OR = 3.33; 95 % CI: 1.14-9.45; p = 0.033) genetic models. It should be noted that racial/ethnic diversity represents an important factor in the variability observed in the studies of SNPs, and other factors such as sample size, gender, or cut-off points for the classification of obesity can also provide variation in results.

Few studies have carried out a functional analysis of this polymorphism. Transcription factor Sp1 regulates the expression of a large number of genes, including adiponectin promoter activity (30). Zhang et al. found that the G-allele of the ADIPOQ 11377 C>G polymorphism altered the sequence for one of the Sp1 binding sites, which consequently resulted in the loss of the Sp1 binding effect, and might play a role in the reduction of adiponectin promoter transcription activity (9). Further studies are required to elucidate the consequences of this SNP at the protein level and its interaction with other cellular components in the context of metabolic syndrome and diseases related to obesity.

Mexico is a country with a large amount of genetic diversity, and has a high prevalence of obesity, as well as of risk factors associated with MetS. An advantage of this study is that the selection of patients and controls was only performed in the western part of the country. A weakness of the study is the relatively small number of samples. Quantification of serum levels of adiponectin based on genotype would be useful to compare the effects of the ADIPOQ 11377 C>G polymorphism in MetS patients.

CONCLUSION

Our findings suggest that the minor allele G of the ADIPOQ 11377 C>G polymorphism constitutes a risk factor for the development of MetS under the codominant, dominant, and recessive models in a Mexican population of western Mexico.

REFERENCES

1. WHO. Obesity and overweight. [Access 16 February 2018]. Available from: http://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight.
2. Shamah-Levy T, Ruiz-Matus C, Rivera-Dommarco J, Kuri-Morales P, Lucia LCN, Jiménez-Corona ME, et al. National Health and Nutrition Examination Survey 2016 Half Way. National Results. In: d.s.P.O (México): Guanica, Méxic; 2017.
3. Rivelade Z, Marsh T, Barquera S, Sanchez Romero LM, Levy D, Melen- dez G, et al. Obesity prevalence in Mexico: impact on health and economic burden. Public Health Nutrition 2013;17(1):233-9. DOI: 10.1017/ S1368946213000086
4. Kaur J. A Comprehensive Review on Metabolic Syndrome. Cardiol Res Pract 2014;2014:943162. DOI: 10.1155/2014/943162
5. Han TS, Lean ME. A clinical perspective of obesity, metabolic syndrome and cardiovascular disease. JRSM Cardiovascular disease 2016;5:204800401663371. DOI: 10.1177/204800401663371
6. Hanwood HJ. The adipocyte as an endocrine organ in the regulation of metabolic homeostasis. Neuropharmacology 2012;63(1):57-75. DOI: 10.1016/j. neuropharm.2011.12.010
7. Vasseur F. The genetics of adiponectin. International Congress Series 2003;1253: 37-44. DOI: 10.1016/S0363-5133(03)00137-7
8. Maury E, Brichard SM. Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome. Molecular and Cellular Endocrinology 2010;314(1):1-16. DOI: 10.1016/j.mce.2009.07.031
9. Zhang D, Ma J, Brismar K, Efendic S, Gu HF. A single nucleotide polymorphism alters the sequence of Sp1 binding site in the adiponectin promoter region and is associated with diabetic nephropathy among type 1 diabetic patients in the Genetics of Kidney in Diabetes Study. Journal of Diabetes and its Complications 2009;23(4):265-72. DOI: 10.1016/j.jdiacomp.2008.05.004
10. Divella R, Daniele A, Mazzocca A, Abbate I, Casamassima P, Caliandro C, et al. ADIPOQ rs266729 G/C gene polymorphism and plasmatic adipocytokine levels in non-diabetic and diabetic obese subjects. Diabetic Medicine 2004;21(5):497-9. DOI: 10.1111/j.1464-2257.2004.01178.x
11. Grundy SM, Brewer HB, Cleeman JJ, Smith SC, Lantert C. Definition of Metabolic Syndrome. Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004;109(3):433-8. DOI: 10.1161/01. CRT.0000111245.75752.CB
12. World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. JAMA 2013;310(20):2191-4. DOI: 10.1001/jama.2013.80436
13. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic acids research 1988;16(3):1215.
14. Silha Jv, Krsek M, Skrha J, Sucharda P, Nyomba BG, Murphy LJ. Plasma resistin, leptin and adiponectin levels in non-diabetic and diabetic obese subjects. Diabetic Medicine 2004;21(5):497-9. DOI: 10.1111/j.1464-5491.2004.01178.x
15. Schulez MB, Rimm EB, Shai I, Rifai N, Murphy LJ. Plasma resistin, leptin and adiponectin levels in non-diabetic and diabetic obese subjects. Diabetic Medicine 2004;21(5):497-3. DOI: 10.1111/j.1464-5491.2004.01178.x
16. Mojiminiyi OA, Abdella NA, Al Arouj M, Ben Nakhli A. Adiponectin, insulin resistance and clinical expression of the metabolic syndrome in patients with Type 2 diabetes. International Journal Of Obesity 2006;31:213. DOI: 10.1038/sj.ijo.0803355
17. Mohamed A, Ahmed, Pradeepa R, Vimalasaran KS, Mohan A, Velumurugan K, et al. Association of low adiponectin levels with the metabolic syndro- me in the Chennai Urban Rural Epidemiology Study (CURES-4). Metabolism - Clinical and Experimental 2005;54(4):476-81. DOI: 10.1016/j. metabol.2004.10.016
18. He Y, Lu L, Wei X, Jin D, Qian T, Yu A, et al. The multimerization and secretion of adiponectin are regulated by TNF-alpha. Endocrine 2016;51(3):456-68. DOI: 10.1007/s12020-015-0741-4

19. Wensveen FM, Valentí S, Sestan M, Turk Wensveen T, Polić B. The “Big Bang” in obese fat: Events initiating obesity-induced adipose tissue inflammation. European Journal of Immunology 2015;45(9):2446-56. DOI: 10.1002/eji.201545502

20. Calton EK, Miller VS, Soares MJ. Factors determining the risk of the metabolic syndrome: is there a central role for adiponectin? European Journal of Clinical Nutrition 2013;67(S):485-91. DOI: 10.1038/ejcn.2013.1

21. Gu HF. Biomarkers of adiponectin: plasma protein variation and genomic DNA polymorphisms. Biomarker insights 2009;4:123-33.

22. Vasseur F, Helbecque N, Lobbens S, Vasseur-Delannoy V, Dina C, Clément K, et al. Hypoadiponectinaemia and high risk of type 2 diabetes are associated with adiponectin-encoding (ACDC) gene promoter variants in morbid obesity: evidence for a role of ACDC in diabetes. Diabetologia 2005;48(9):892-9. DOI: 10.1007/s00125-005-1729-z

23. Yang M, Qiu CC, Chen W, Xu LL, Yu M, Xiang HD. Identification of a Regulatory Single Nucleotide Polymorphism in the Adiponectin (APM1) Gene Associated with Type 2 Diabetes in Han Nationality. Biomedical and Environmental Sciences 2008;21(6):454-9. DOI: 10.1016/S0895-3988(09)60002-7

24. Gu HF, Abulaiti A, Östenson CG, Humphreys K, Wahlestedt C, Brookes AJ, et al. Single Nucleotide Polymorphisms in the Proximal Promoter Region of the Adiponectin (APM1) Gene Are Associated With Type 2 Diabetes in Swedish Caucasians. Diabetes 2004;53(suppl 1):S31. DOI: 10.2337/diabetes.53.2007.531

25. de Luis DA, Primo D, Izola O, Gómez Hoyos E, Lopez-Gomez JJ, Ortolà A, et al. Role of the variant in adiponectin gene rs266729 on weight loss and cardiovascular risk factors after a hypocaloric diet with the Mediterranean pattern. Nutrition 2019;60:1-5. DOI: 10.1016/j.nut.2018.08.018

26. de Luis DA, Primo D, Izola O, Aller R. Effect of two different dietary fatty acid profiles and variant rs266729 in ADIPOQ on weight loss and adiponectin concentrations. Endocrinología, Diabetes y Nutrición 2020;67(6):374-82. DOI: 10.1016/j.endinu.2019.09.004

27. de Luis DA, Primo D, Izola O, Aller R. Adiponectin Gene Variant rs266729 Interacts with Different Macronutrient Distribution of Two Different Hypocaloric Diets. Lifestyle Genom 2020;13(1):29-7. DOI: 10.1159/000503863

28. Gasparotto A, Borges D, Zandonà M, Ramos M, Meirhaert N, Mattevi V. Adiponectin promoter polymorphisms are predictors of lipid profile improvement after bariatric surgery. Genetics and Molecular Biology 2017; 40(4):736-42. DOI: 10.1590/1678-4685-gmb-2016-0241

29. Zhou JM, Zhang M, Wang S, Wang BY, Han CY, Ren YC, et al. Association of the ADIPOQ Rs2241766 and Rs266729 Polymorphisms with Metabolic Syndrome in the Chinese Population: A Meta-analysis. Biomedical and Environmental Sciences 2016;29(7):505-15. DOI: 10.3967/bes2016.066

30. Barth N, Langmann T, Schölmerich J, Schmitz G, Schäffler A. Identification of regulatory elements in the human adipose most abundant gene transcript-1 (apM-1) promoter: role of SP1/SP3 and TNF-α as regulatory pathways. Diabetologia 2002;45(10):1425-33. DOI: 10.1007/s00125-002-0895-5